Thrombin inhibits osteoclast differentiation through a non-proteolytic mechanism

S Sivagurunathan, C N Pagel*, L H Loh, L C Wijeyewickrema1, R N Pike1 and E J Mackie

Faculty of Veterinary Science, University of Melbourne, Parkville, Victoria 3010, Australia
1Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia
*(S Sivagurunathan and C N Pagel contributed equally to this work)

Correspondence should be addressed to E J Mackie
Email ejmackie@unimelb.edu.au

Abstract

Thrombin stimulates expression of interleukin 6 and cyclooxygenase 2 by osteoblasts, both of which enhance osteoblast-mediated osteoclast differentiation by increasing the ratio of receptor activator of nuclear factor κB ligand (RANKL) expression to that of osteoprotegerin (OPG) in osteoblasts. We hypothesised that thrombin would also increase this ratio and thereby stimulate osteoclast differentiation in mixed cultures of osteoblastic cells and osteoclast precursors. In primary mouse osteoblasts, but not in bone marrow stromal cells, thrombin increased the ratio of RANKL to OPG expression. Thrombin inhibited differentiation of osteoclasts, defined as tartrate-resistant acid phosphatase (TRAP)-positive cells with three or more nuclei, in mouse bone marrow cultures treated with osteoclastogenic hormones; this effect was not mediated by the major thrombin receptor, protease-activated receptor 1, nor did it require thrombin’s proteolytic activity. Thrombin also caused a decrease in the number of TRAP-positive cells with fewer than three nuclei. Thrombin (active or inactive) also inhibited osteoclast differentiation and bone resorption, respectively, in cultures of mouse spleen cells and human peripheral blood mononuclear cells induced to undergo osteoclastogenesis by treatment with RANKL and macrophage colony-stimulating factor. Osteoclast differentiation in spleen cells was inhibited when they were exposed to thrombin from days 0 to 3 or 3 to 5 of culture but not days 5 to 7 when most fusion occurred. Thrombin inhibited expression of RANK by spleen cells. These observations indicate that, although thrombin stimulates production of osteoclastogenic factors by osteoblastic cells, it inhibits the early stages of RANKL-induced osteoclast differentiation through a direct effect on osteoclast precursors that does not require thrombin’s proteolytic activity.

Key Words
- thrombin
- osteoclast
- protease-activated receptor 1
- RANKL
- osteoprotegerin

Introduction

Osteoclasts, the multinucleate cells responsible for bone resorption, are derived from the monocyte-macrophage lineage of haemopoietic cells. The other major bone cell lineage is that of the bone-forming osteoblasts. Osteoblasts and their precursors express two factors that are essential for osteoclast differentiation and activity: macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor κB ligand (RANKL) (Ross 2008). Many factors that stimulate osteoclast differentiation, including parathyroid hormone (PTH), prostaglandin E2 (PGE2), 1,25-dihydroxyvitamin D3 (1,25D) and interleukin 6 (IL6), do so by stimulating an increase in
The blood coagulation protease, thrombin, exerts hormone-like effects on cells including osteoblasts. For example, thrombin stimulates proliferation and inhibits apoptosis of cultured osteoblasts (Tatakis et al. 1989, Abraham & Mackie 1999, Pagel et al. 2003). Thrombin also stimulates expression of IL6 and cyclooxygenase 2 (COX2) mRNA, as well as IL6 and PGE2 secretion by osteoblasts (Feyen et al. 1984, Kozawa et al. 1997, Pagel et al. 2009). Thrombin’s stimulation of osteoblastic proliferation and IL6 and PGE2 release are mediated by protease-activated receptor 1 (PAR1), a member of the PAR group of seven-transmembrane domain G protein-coupled receptors (Abraham & Mackie 1999, Song et al. 2005b, Pagel et al. 2009). PARs are activated by proteolytic cleavage of their extracellular domain, creating a new N-terminus that binds to the second extracellular loop of the same receptor molecule, thus activating intracellular signalling pathways (Mackie et al. 2008). Thrombin’s inhibition of osteoblast apoptosis, by contrast, is not mediated by any of the PARs although it is dependent on an interaction between proteolytically active thrombin and the cells (Pagel et al. 2003).

In the bone environment, active thrombin is generated upon initiation of blood coagulation as a result of bone fracture, as well as in rheumatoid arthritis and possibly other inflammatory conditions affecting bone such as periodontal disease (Mackie et al. 2008). It is thus important to understand the full range of responses of bone cells elicited by this potent biological agent. The current study was initiated to investigate the hypothesis that thrombin-induced secretion of IL6 and PGE2 leads to an increase in the ratio of RANKL:OPG in osteoblastic cells and thus increased osteoclast differentiation in mixed populations of cells of the osteoblast and osteoclast lineages. When it was determined that, contrary to expectations, thrombin inhibits osteoclast differentiation induced by a variety of osteoclastogenic factors, further studies were undertaken to investigate the mechanism of the effect.

Materials and methods

Materials

Tissue culture media and heparin sodium salt were purchased from Gibco–Invitrogen (Life Technologies). FCS was purchased from JRH Bioscience (Lenexa, KS, USA). Recombinant human and mouse RANKL were from PeproTech Asia (Rehovot, Israel). Recombinant human and mouse M-CSF were from R&D Systems (Minneapolis, MN, USA). PGE2 was obtained from Cayman Chemicals (Ann Arbor, MI, USA). All reagents for PCR were obtained from Promega. Primers and oligonucleotides were custom synthesised by Geneworks (Adelaide, SA, Australia). The thrombin inhibitor d-phenylalanyl-L-prolyl-L-arginine-chloromethyl ketone (PPACK) was obtained from Calbiochem (San Diego, CA, USA). Rabbit thrombomodulin was obtained from Haematologic Technologies, Inc. (Essex Junction, VT, USA). Hirudin fragment 54–65 and all other chemicals and reagents were purchased from Sigma–Aldrich unless otherwise stated.

Thrombin from three different sources was used in the study. Human plasma z-thrombin was purified as described by Stone & Hofsteenge (1986). Any contaminating lipopolysaccharide was removed using a Detoxi-Gel column (Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer’s instructions. The active concentration of thrombin was determined as described by Pagel et al. (2009). Human z-thrombin was also purchased from Haematologic Technologies, Inc., and recombinant human z-thrombin was expressed and purified as described by Johnson et al. (2005). The data presented in the paper were obtained with thrombin purified by the authors, unless otherwise indicated. Thrombin was used at a concentration of 100 nmol/l unless otherwise specified. Catalytically inactive thrombin was prepared by incubating thrombin (100 nmol/l) with PPACK (1 μmol/l) for 15 min at 37 °C; inactivation was confirmed by thrombin activity assays using the chromogenic substrate S-2238, as described by Pagel et al. (2003). The purity of thrombin preparations was confirmed by comparing their appearance on silver-stained gels with that on western blots, prepared as described below; for all sources of thrombin, all bands visible on the silver-stained gels were visible on western blots (Fig. 1).

Mice

PAR1-null (Connolly et al. 1996) mice on the C57BL/6J background were kindly provided by Dr S R Coughlin (University of California, San Francisco, USA). The breeding colony is maintained through heterozygous mating at the Faculty of Veterinary Science, University of Melbourne; mice used for primary cell culture were either littermates or the offspring of littermates. All work involving primary culture of mouse cells was approved by the Animal Ethics Committee of the University of Melbourne.
Cell culture

Primary calvarial osteoblasts were collected by sequential collagenase digestion of calvariae from PAR1-null and wild-type mice as described by Pagel et al. (2003). Cells were maintained in DMEM with 10% (v/v) heat-inactivated FCS, 1-glutamine (300 μg/ml), gentamicin (50 μg/ml) and amphotericin B (2.5 μg/ml). The medium was changed every second day and cultures were maintained in a humidified atmosphere at 37 °C under 5% CO2 in air. At first passage, osteoblasts were plated in six-well plates for RNA extraction. Following attachment, cells to be used for RNA extraction were treated with serum-free medium in the absence or presence of thrombin.

Bone marrow cells were prepared from tibiae and femurs of 6- to 9-week-old PAR1-null and wild-type mice as described by Smith et al. (2004). The marrow cavity was flushed with an α-minimum essential medium (α-MEM) with penicillin (0.03 g/l), streptomycin (0.01 g/l) and 10% (v/v) heat-inactivated FCS (α-MEM/FCS). In some experiments, bone marrow stromal cells were allowed to adhere to plastic-culture-ware surfaces for 48 h before harvesting by trypsinisation.

For the culture of whole bone marrow, cells were washed and cultured in α-MEM/FCS in 24-well plates containing glass coverslips at 2×10⁶ cells/ml in a volume of 500 μl. Treatments consisting of various combinations (as indicated in the Results section) of human PTH 1–34 (10 nmol/l), 1,25D (10 nmol/l), PGE2 (1 μmol/l), thrombin (100 nmol/l), PPACK (1 μmol/l) and PPACK-inactivated thrombin (100 nmol/l unless otherwise specified) were added after a 24 h attachment period and at each medium change. Cultures were maintained by removing 450 μl medium and replacing with 500 μl fresh medium every 3 days. Cultures were maintained for 7–10 days.

Bone marrow stromal cells were plated in six-well plates at 10⁶ cells/well and cultured in a serum-free α-MEM for 24 h before treatment with thrombin (100 nmol/l) for 24 h. Media, conditioned by control and thrombin-treated bone marrow stromal cells, were collected and cells were either lysed for ELISA in phosphate buffer containing 1% Triton X or were lysed for RNA preparation as described below.

Spleen cells were isolated from 6- to 9-week-old PAR1-null and wild-type mice (Li et al. 2000, Okada et al. 2000) using a cell strainer (70 μm; BD Bioscience, San Jose, CA, USA). The cell suspension was pelleted and resuspended in α-MEM/FCS. T cells were removed from mouse spleen cells using mouse pan T (Thy 1.2) Dynabeads (Life Technologies; John et al. 1996). In some experiments, the remaining spleen cells were plated at 5×10⁵ cells/well in a 48-well plate containing glass cover slips and then cultured with mouse RANKL (25 ng/ml) and mouse M-CSF (50 ng/ml) together with various combinations of thrombin (100 nmol/l), PPACK (1 μmol/l), PPACK-inactivated thrombin (100 nmol/l), hirudin fragment 54–65 (10 μmol/l), heparin (100 μg/ml), thrombomodulin (400 nmol/l) or vehicle in α-MEM/FCS for 7 days, unless otherwise indicated; in experiments involving hirudin fragment, heparin and thrombomodulin, polymixin B (10 μmol/l) was included in all treatments to inactivate any lipopolysaccharide that may have been present in these reagents; these cultures were then stained for the presence of osteoclasts (described below). In some experiments, the T cell-depleted spleen cells were plated in six-well plates (6.4×10⁶ cells/well) and treated with RANKL and M-CSF together with vehicle or thrombin for 1, 3 or 5 days, before RNA extraction.

Human osteoclasts were cultured from buffy coats of donor blood (Australian Red Cross, Melbourne, VIC, Australia), diluted 1:1 in PBS, layered over 10 ml Ficoll-Hypaque (GE Healthcare Life Sciences, Piscataway, NJ, USA) and centrifuged at 900 g for 30 min. A layer of monocytes was extracted from the interface of the PBS and Ficoll-Hypaque and centrifuged at 400 g for 5 min. The cell pellet was rinsed and washed in α-MEM/FCS. Cells were counted using a haemocytometer to determine the

**Figure 1**

Gel electrophoresis of thrombin preparations. Thrombin preparations were subjected to SDS–PAGE followed by silver staining (left) or transferred to nitrocellulose and probing with anti-thrombin antibody and detection by chemiluminescence (right). Lane 1, recombinant human thrombin; Lane 2, human plasma thrombin purified by the authors and Lane 3, commercial human plasma thrombin. M, molecular weight markers.
number of mononuclear cells. Peripheral blood mononuclear cells (PBMCs) were seeded in 96-well plates containing dentine slices (4×4×0.2 mm) at a concentration of 1×10^6 cells/well in α-MEM/FCS. After incubation at 37 °C for 2 h, the cells were rinsed twice with α-MEM/FCS to remove any non-attached cells. Cells were cultured for 21 days in 150 μl-α-MEM/FCS containing human RANKL (30 ng/ml), human M-CSF (25 ng/ml) and thrombin or vehicle; thrombin was present in the medium for the full culture period unless otherwise indicated.

Identification of osteoclasts

Histochemical staining for the osteoclast marker tartrate-resistant acid phosphatase (TRAP) was used to assist in the identification of osteoclasts in cultures. At the end of the culture period, cells were fixed with 4% (w/v) paraformaldehyde in PBS for 3 min and 1:1 acetone/ethanol for 30 s and then stained for acid phosphatase using naphthol AS-TR phosphate (Minkin 1982) and then mounted in aqueous mountant containing 4',6-diamidino-2-phenylindole (DAPI; 1 μg/ml). Osteoclasts were counted as TRAP-positive multinucleate cells (cells with three or more nuclei; TRAP+MNC); results are expressed as TRAP+MNC/dentine slice or well. The number of DAPI-positive nuclei present in cultures was determined from three random fields for each well. Low-power digital images were captured and the number of fluorescent objects per field was counted using Image-Pro Plus version 4.1 (Media Cybernetics, Rockville, MD, USA). Results for each treatment are presented as mean number of nuclei per field from three wells.

Resorption was assayed by assessing the ability of human PBMCs cultured for 21 days to form resorption pits on the surface of dentine slices. At the end of the culture period, cells were removed and processed for scanning electron microscopy as described by Sivagurunathan et al. (2005). Dentine slices were sputter-coated with gold with an Edwards S 150B sputter coater and examined using a Philips XL Field Emission Scanning Electron Microscope; digital images were collected for each slice. Using Image-Pro Plus version 4.1 (Media Cybernetics), a grid was placed over each micrograph. The total number of points on each grid provided a measure of total area, and the number of points overlying resorption pits was counted as a measure of resorption area, which was expressed as a percentage of total area (Howard & Reed 1998). For each dentine slice, four random areas were chosen to estimate the percentage area resorbed.

Plasmid construction, RNA extraction and quantitative RT-PCR

Oligonucleotide primers for detection of expression of RANKL, OPG and a number of osteoclast genes were designed using Primer3 Software (http://primer3.sourceforge.net/) and are presented in Table 1. The sequences of primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were as described by Pagel et al. (2009).

RNA samples from calvarial osteoblasts were used to amplify RANKL and OPG genes with BIOTAQ DNA polymerase (Bioline, London, UK) according to the manufacturer’s instructions, and the products were purified using a Wizard SV Gel and PCR clean-up system (Promega) according to the manufacturer’s instructions. The purified products were cloned into pGEM-T easy vector (Promega) and the recombinant plasmids were transformed into XL1 Blue competent cells (Agilent Technologies, Santa Clara, CA, USA) for antibiotic selection and DNA preparation. Purified plasmids were linearised by EcoR1 restriction digestion, and DNA was quantified by absorbance at 260 nm. Serial dilutions of the linearised plasmid were made from 10^6 to 10^3 single-stranded DNA molecules/μl for the construction of a standard curve for each experiment involving quantification of RANKL and OPG expressions (Smith et al. 2003, Tsubakihara et al. 2004).

Total RNA was isolated from cell layers by lysis, using the SV Total RNA isolation system (Promega). First-strand synthesis of cDNA was performed using 1 μg total RNA primed with Oligo dT \textsubscript{15} (Promega) in 25 μl reactions.

**Table 1** Primer sequences

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer (5’–3’)</th>
<th>Reverse primer (5’–3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OPG (Tnfrsf11b)</td>
<td>GAA CCC CAG AGC GAA ATA CA</td>
<td>CCT GAA GAA TGG CTC TCA CCA AC</td>
</tr>
<tr>
<td>RANKL (Tnfsf11)</td>
<td>CAT TTG CAC ACC TCA CCA TC</td>
<td>GTG TCT CCT CCT TCG AGC ATG</td>
</tr>
<tr>
<td>RANK (Tnfrsf11a)</td>
<td>CTG ATG AGA GGG GAG CCT CA</td>
<td>TGA AGT TCA TCA CCT GCC CG</td>
</tr>
<tr>
<td>Oscar</td>
<td>TGT CGA TCT TCT GTG AGC GGT</td>
<td>GAT CCC AGG AGT CAC AAC AC</td>
</tr>
<tr>
<td>c-fos (Fos)</td>
<td>ATG GGC TCT CCT GTC AAC AC</td>
<td>TGT CAC CGT GGG GAT AAA GT</td>
</tr>
<tr>
<td>c-fms (Gsf1r)</td>
<td>CGA GGG AGA CTC CAG CTA CA</td>
<td>GCT GGT CAA CAG CAC GTC TC</td>
</tr>
</tbody>
</table>
including 5 μl of 5× reverse transcriptase buffer, dNTPs (2 nmol/l) and 100 U MM-LV reverse transcriptase (RNase H; all from Promega); the reaction was carried out according to the manufacturer’s instructions. Quantitative RT-PCR (qRT-PCR) reactions were performed in a total volume of 20 μl, with 10 μl Applied Biosystems SYBR Green PCR Master Mix (Life Technologies), forward and reverse primers (each 250 nmol/l) and 2 μl cDNA template in accordance with the manufacturer’s instructions. Reactions were performed on an MX3000p Real-Time PCR Machine (Agilent Technologies) by denaturing at 95 °C for 15 min, followed by 40–70 cycles of denaturation at 95 °C for 30 s, annealing at 60 °C for 30 s and extension at 72 °C for 30 s. RANKL and OPG gene expressions were analysed by absolute quantification; varying concentrations of plasmid DNA (10², 10³, 10⁴, 10⁵ and 10⁶ copies/μl) were used to create a standard curve. The quantity of target gene in the samples was determined from the standard curves using MX3000p Real-Time PCR Machine Software and expressed as copies/μg RNA. The expression of osteoclast genes was normalised to that of GAPDH and data are presented as mean-normalised expression calculated using the Q-Gene Software (http://www.gene-quantification.de/) application (Muller et al. 2002).

**Protein gel electrophoresis**

RANKL (30 ng/ml) and M-CSF (25 ng/ml) in PBS containing 0.1% (w/v) BSA were incubated with thrombin (100 nmol/l) for 30 min at 37 °C before the thrombin inhibitor PPACK (Calbiochem) was added to a final concentration of 1 μmol/l; the mixture was incubated for 15 min at 37 °C. The protein mixture was then subjected to 12% SDS–PAGE and transferred onto nitrocellulose membranes (GE Healthcare Life Sciences) or silver staining (Morrissey 1981). Nitrocellulose membranes were incubated with monoclonal anti-human RANKL antibody (R&D Systems) or sheep anti-bovine thrombin antibody (Affinity Biologicals, Ancaster, ON, Canada), followed by incubation with anti-mouse HRP (Dako A/S, Glostrup, Denmark). The results were visualised using an ECL Chemiluminescence Detection Kit (GE Healthcare).
Life Sciences). Immunoreactive proteins were visualised using a Chemi-Smart 2000 (Vilber Lourmat, Marne-la-Vallée, France).

**ELISA**

The levels of RANKL and OPG present in bone marrow stromal cell cultures were measured using RANKL and OPG ELISA kits (R&D Systems) in accordance with the manufacturer’s instructions. The amounts of RANKL and OPG present in cell lysates and conditioned medium from each well were combined to give a total value per well.

**Statistical analysis**

Data are presented as the mean ± S.E.M. Data were analysed by two-tailed Student’s t-test, one-way ANOVA and Dunnett’s post-hoc test or two-way ANOVA or Bonferroni’s post-hoc test, as appropriate, except for qRT-PCR results for osteoclast genes, which were analysed for significant differences by a 2000 sample, pairwise fixed reallocation randomisation test, using REST-384 free software (Pfaffl et al. 2002). All data presented here are representative results of at least two similar experiments.

**Results**

**The effect of thrombin on the expression of RANKL and OPG**

The expression of OPG and RANKL mRNA was quantified by absolute qRT-PCR in primary calvarial osteoblasts treated with or without thrombin for 24 h in a serum-free medium. Thrombin, used at a concentration (100 nmol/l) that stimulates maximal responses of osteoblasts and bone marrow stromal cells in a variety of assays (Pagel et al. 2003, Song et al. 2005a), had no effect on the expression of RANKL mRNA but significantly suppressed the expression of OPG mRNA and thus significantly increased the ratio of RANKL:OPG (Fig. 2A). By contrast, in bone marrow stromal cells, thrombin stimulated both RANKL and OPG expressions, as detected by ELISA, resulting in no significant change in the ratio of RANKL:OPG (Fig. 2B); this ratio was similarly unchanged in qRT-PCR studies on bone marrow stromal cells (data not shown).

**The effect of thrombin on osteoclast differentiation**

The ability of thrombin to modulate osteoclastogenesis was initially investigated in murine bone marrow cultures, because bone marrow contains both osteoclast precursors and the stromal cells of the osteoblast lineage capable of expressing the RANKL and M-CSF that are necessary for osteoclast differentiation. The effect of thrombin on osteoclast differentiation was investigated in cells isolated from wild-type mice and treated with or without PTH or 1,25D and PGE2 for 10 days. In the absence of these osteoclastogenic factors, no TRAP+MNC were formed, whether or not thrombin was present; in cultures treated with PTH or 1,25D and PGE2, thrombin significantly decreased the number of TRAP+MNC (Fig. 3A). Thrombin exerted a similar effect on bone marrow cells isolated from PAR1-null mice (Fig. 3B). Moreover, catalytically inactive (PPACK-treated) thrombin, like active thrombin, was able to inhibit the formation of TRAP+MNC (Fig. 3B).

In dose–response studies, a maximal response to thrombin was obtained with a concentration of
300 nmol/l, but as this is close to the maximum concentration detected in clotted blood (Rand et al. 1996) and as the response to 100 nmol/l thrombin was close to maximal, the latter concentration was used for further experiments (Fig. 4A). The initial experiments were undertaken with thrombin purified from human plasma by the authors, but similar results were obtained with human plasma thrombin from a commercial source and with recombinant human thrombin (Fig. 4B). As with TRAP+MNC, there were fewer TRAP-positive cells with fewer than three nuclei in thrombin-treated than in control cultures (Fig. 4C and D).

**Are osteoclast precursors the direct target of thrombin’s inhibitory activity?**

The fact that thrombin inhibited osteoclast differentiation in bone marrow cultures, although not influencing the RANKL:OPG ratio in bone marrow stromal cells, could perhaps be explained by osteoclast precursors being the direct target of thrombin’s inhibitory activity. The effect of thrombin on osteoclast differentiation in spleen cells treated with RANKL and M-CSF was, therefore, investigated. In wild-type spleen cell cultures, thrombin significantly inhibited the formation of TRAP+MNCs and a similar effect was observed in PAR1-null spleen cell cultures (Fig. 5A). Catalytically inactive thrombin also inhibited the formation of TRAP+MNCs in both wild-type and PAR1-null cultures (Fig. 5A).

Osteoclastogenesis is a multistep process, which involves proliferation of osteoclast precursors, followed by early differentiation as mononuclear cells, then fusion to form multinucleated osteoclasts. Mouse spleen cells induced to differentiate into osteoclasts were treated with thrombin for different times within the culture period, to determine which stage is affected by the presence of thrombin. In these experiments, thrombin was present for the entire culture period (0–7 days), or throughout the proliferative phase (0–3 days), differentiation phase (3–5 days) or fusion phase (5–7 days). When spleen cells were cultured with thrombin either for the first 3 days or between days 3 and 5, the number of TRAP+MNCs formed was similar to that observed in cultures treated with thrombin for the entire culture period. (A) Dose–response to thrombin. (B) Effect of thrombin from different sources. (C) Effect of thrombin on TRAP+ cells with fewer than three nuclei. (D) Representative images of cultures. The magnification is the same in both images; bar = 100 μm. Data are presented as mean ± S.E.M. (n = 3). Statistical analysis was performed using one-way ANOVA with Dunnett’s multiple comparison test (B) and two-tailed Student’s t-test (C): *P < 0.05 and **P < 0.01 for comparisons between treatment and control values.
Thrombin inhibits osteoclast differentiation: investigation of structural requirements

When we first observed that thrombin inhibited osteoclast differentiation independently of PAR₁, it occurred to us that thrombin may simply be acting through degradation of the RANKL or M-CSF produced by osteoblastic cells in bone marrow cultures and added to the culture medium in cultures of spleen cells or PBMCs. The finding that PPACK-inactivated thrombin was equally capable of inhibiting osteoclast differentiation appeared to rule out this possibility, but we chose to verify this conclusion using a second approach. RANKL or M-CSF were incubated with thrombin under conditions mimicking the culture conditions, then investigated for proteolysis using SDS–PAGE, followed by western blotting (for RANKL) or silver staining (for M-CSF). Thrombin treatment had no effect on the size of the bands observed for either of these proteins (Fig. 7A).

Thrombin’s structure includes, in addition to the active site, exosites that assist in interactions with substrates and inhibitors and determine the specificity of such interactions. The possible involvement of these exosites in mediating thrombin’s effect on osteoclast precursors was therefore examined in cultures of mouse spleen cells treated with RANKL and M-CSF, using hirudin fragment 54–65 (10 μmol/l); an exosite I ligand), heparin (100 μg/ml; an exosite II ligand) and thrombomodulin (200 nmol/l; binds exosites I and II). Neither the hirudin fragment nor heparin affected thrombin’s ability to inhibit the formation of TRAP+MNCs (Fig. 7B). Thrombomodulin alone significantly inhibited the formation of osteoclasts, thus it was not possible to determine whether it influenced thrombin’s inhibitory activity (Fig. 7B).

Figure 5
Effect of thrombin on osteoclast differentiation in mouse spleen cells. Spleen cells were cultured for 7 days (A and B) or 3, 5 and 7 days (C) in the presence of RANKL and M-CSF, then analysed for the presence of TRAP+MNCs (A and B) or all adherent cells (C). (A) Spleen cells derived from either wild-type or PAR₁ null mice were treated with or without thrombin (100 nmol/l); PPACK (1 μmol/l) or PPACK-inactivated thrombin (100 nmol/l) for 7 days. (B) Spleen cells from wild-type mice; thrombin (100 nmol/l) was excluded from the medium (control), or included for 7 days (0–7), for the first 3 days (0–3), between days 3 and 5 (3–5) or between days 5 and 7 (5–7). (C) Spleen cells from wild-type mice were treated with or without commercial thrombin (100 nmol/l); the total number of nuclei in adherent cells was counted. Results are expressed as mean ± S.E.M. (n = 5 in (A and B); n = 3 in (C)). Statistical analysis was performed using two-way ANOVA with Bonferroni’s post-hoc test (A and C) and one-way ANOVA with Dunnett’s multiple comparison test (B); ***P < 0.001 for comparisons indicated by lines in (A); NS, not significantly different; **P < 0.01 for comparisons between treatment and control values in (B).

period, i.e. significantly lower than in controls (Fig. 5B). However, the presence of thrombin between days 5 and 7 did not inhibit the formation of TRAP+MNCs (Fig. 5B). In another experiment, some control cultures were stopped at day 5 as well as at day 7; in this experiment, there were significantly more (P < 0.05; t-test) TRAP+MNCs at day 7 (187 ± 28) than at day 5 (75 ± 4), confirming that the majority of fusion occurred from days 5 to 7. The total number of nuclei in adherent cells was counted in spleen cell cultures at days 3, 5 and 7; there was no significant difference between thrombin-treated and control cultures at any time point (Fig. 5C).

The ability of thrombin to inhibit differentiation of human osteoclasts was also investigated. Human PBMCs were cultured on dentine slices in the presence of RANKL and M-CSF; the slices were then processed for scanning electron microscopy and the area of resorption pits was measured (Fig. 6). Treatment with thrombin (either active or inactive) for the full 21-day culture period caused a significant reduction in resorption area, and the pits that were present were smaller than in control cultures (Fig. 6C and D). In this culture system, resorption commences between days 14 and 21 and continues thereafter (Sivagurunathan et al. 2005). Some cultures were maintained for 16 days in the absence of thrombin and then in the presence of thrombin for the remainder of the culture period; in these cultures, the resorption area was not significantly different from that of control cultures (Fig. 6E).
Effect of thrombin on expression of osteoclast genes

The ability of thrombin to influence the expression of genes expressed by cells of the osteoclast lineage that are essential for osteoclast differentiation was investigated by qRT-PCR in spleen cell cultures treated with RANKL and M-CSF for 1, 3 or 5 days. Thrombin had no effect on mRNA expression of c-fms (the M-CSF receptor), c-fos or Oscar (data not shown), but in thrombin-treated cultures there was no detectable RANK expression at day 3 or 5, whereas it was present in control cultures (Fig. 8).

Discussion

Thrombin has previously been shown to stimulate the release of osteoclastogenic factors such as IL6 and prostaglandins by osteoblasts. This leads to our hypothesis that thrombin-induced secretion of IL6 and PGE2 gives rise to an increase in the ratio of RANKL:OPG in osteoblastic cells and thus increased osteoclast differentiation in mixed populations of cells of the osteoblast and osteoclast lineages, such as are found in bone marrow. Initial experiments confirmed that thrombin does indeed cause an increase in the ratio of RANKL:OPG in osteoblasts, but similar experiments with mouse bone marrow stromal cells demonstrated that thrombin does not influence the ratio in these less differentiated cells. Thus, when it was observed that, rather than inducing osteoclast differentiation in bone marrow cultures, as originally predicted, thrombin-inhibited osteoclast differentiation induced by PTH or 1, 25D and PGE2, it seemed likely that this effect may be mediated by a direct effect of thrombin on osteoclast precursors.

The possibility that thrombin exerts direct effects on osteoclast precursors, inhibiting their differentiation, was investigated using two different sources of osteoclast precursors (mouse spleen cells and human PBMCs), in the absence of cells of the osteoblast lineage. As thrombin reproducibly inhibited osteoclast differentiation induced by PTH or 1, 25D and PGE2, it seemed likely that this effect may be mediated by a direct effect of thrombin on osteoclast precursors.

The period during which thrombin is able to inhibit osteoclast formation appears to be in the pre-fusion stages, because thrombin added to spleen cell cultures for...
days 0–3 or 3–5 significantly decreased osteoclast numbers, whereas thrombin present only for days 5–7 had no effect. Thrombin did not influence the number of nuclei in adherent cells at any stage of culture, indicating that it has no effect on adhesion, proliferation or survival, and leading to the conclusion that thrombin exerts its effect by inhibiting pre-fusion differentiation. This conclusion is in accordance with the finding that thrombin completely suppressed expression of RANK mRNA, which would be expected to render the osteoclast precursors unresponsive to RANKL. Further evidence for the conclusion that thrombin has little or no inhibitory effect on fusion is that there were not only fewer TRAP+MNCs in thrombin-treated bone marrow cultures but also fewer TRAP-positive cells with fewer than three nuclei; if thrombin’s major effect was to inhibit fusion, it would be expected that it

Figure 7
Structural requirements for thrombin inhibition of osteoclast differentiation. (A) RANKL (30 ng/ml) or M-CSF (25 ng/ml) were incubated in the absence or presence of thrombin at 37°C for 30 min, then analysed by SDS-PAGE followed by western blotting (RANKL) or silver staining (M-CSF). (B) Spleen cells derived from PAR1 null mice were cultured for 7 days in the presence of RANKL and M-CSF, then analysed for the presence of TRAP+MNCs. Some wells were treated with hirudin fragment 54–65 (Hir/frag; 10 μmol/l), heparin (100 μg/ml) or thrombomodulin (Thr/modulin; 200 nmol/l) in the presence or absence of thrombin (100 nmol/l) for the first 3 days of culture. Statistical analysis was performed using two-way ANOVA with Bonferroni’s post-hoc test (for analysis of the effect of thrombin) and one-way ANOVA with Dunnett’s multiple comparison test (for comparison between inhibitors and control). Results are expressed as mean ± S.E.M. (n = 3–5). NS, not significantly different, **P < 0.01 and ***P < 0.001 for comparisons indicated by lines.

Figure 8
Effect of thrombin on expression of RANK in spleen cell cultures. Spleen cells were cultured for 1, 3 or 5 days in the presence of RANKL and M-CSF in the absence or presence of commercial thrombin (100 nmol/l), then RNA was extracted and analysed by qRT-PCR for expression of RANK. Upper panel: RANK and GAPDH reaction products following 70 cycles were run on agarose gels for visualisation. Lower panel: statistical analysis was performed using REST-384 Software. Results are expressed as mean ± S.E.M. (n = 3). ***P < 0.001 for comparisons indicated by lines.
although PAR₄ is expressed by PBMCs, PAR₄ is not (Colognato et al. 2003), thus ruling out these PARs as possible mediators of thrombin’s effect. The fact that thrombin’s proteolytic activity was not required for its effect on osteoclast differentiation provides further evidence that PARs do not mediate this response.

There is a substantial body of published evidence indicating the existence of at least two non-PAR receptors for thrombin, but these receptors have not been identified. We have demonstrated that thrombin inhibits apoptosis of osteoblasts and skeletal muscle myoblasts independently of any of the PARs (Chinini et al. 1999, Pagel et al. 2003). This effect requires thrombin’s proteolytic activity, thus the receptor involved cannot be the same as that responsible for thrombin’s inhibition of osteoclast differentiation. Proteolysis-independent responses of cells to thrombin have also previously been described. For example, proteolytically inactive thrombin induces chemotaxis of neutrophils and PBMCs and a non-proteolytic thrombin peptide induces cytokine release from PBMCs (Bar-Shavit et al. 1983, Bizios et al. 1986, Crago et al. 1995, Jenkins et al. 1995, Naldini et al. 2004). The receptor responsible for one or all of these effects may also be responsible for thrombin’s inhibition of osteoclast differentiation. Thrombin’s structure includes the RGD sequence that is used by many extracellular matrix proteins to bind to cell adhesion receptors including integrins. When osteoclasts isolated from neonatal rat long bones are plated on different substrata, prothrombin and thrombin selectively support adhesion of small osteoclasts in an RGD-dependent manner, whereas osteopontin and fibronectin support adhesion of larger, more active osteoclasts (Hu et al. 2008). As noted above, thrombin does not appear to have affected cell adhesion in osteoclastogenic cultures in the current study.

The effects of molecules known to interact with well-characterised regions of thrombin outside its active site were investigated to obtain some additional information concerning the interaction of thrombin with osteoclast precursors. From these experiments it can be concluded that neither exosite I nor exosite II is required for thrombin’s inhibition of osteoclast differentiation, because thrombin’s effect was not inhibited by either the hirudin fragment or heparin.

In the current study, thrombin’s inhibition of osteoclast differentiation was reproducible across three different culture systems and two different species, indicating that this is likely to be an important effect of thrombin in vivo. Thrombin is present in coagulated blood immediately following bone injury. We have previously made a number of observations indicating that thrombin supports osteoblastic bone formation at sites of injury: thrombin stimulates proliferation of osteoblasts and bone marrow stromal cells (in a PAR₁-dependent manner); thrombin inhibits apoptosis of osteoblasts and bone marrow stromal cells (in a PAR₁-independent manner); and new bone formation is delayed in PAR₁-null mice following bone injury (Abraham & Mackie 1999, Pagel et al. 2003, Song et al. 2005a,b). The results presented here suggest that while thrombin is supporting rapid new bone formation through its effects on cells of the osteoblast lineage, it is simultaneously suppressing osteoclast differentiation, thus ensuring that the first new bone formed is not immediately removed and has a chance to restore structural integrity as soon as possible. The fact that thrombin was found to inhibit RANKL-induced osteoclast differentiation through direct effects on osteoclast precursors is noteworthy, because it indicates that thrombin is able to counteract the pro-osteoclastogenic effects of the inflammatory milieu of a recent fracture; many pro-inflammatory molecules known to be present in recently injured bone (such as IL6 and prostaglandins) stimulate osteoclast differentiation indirectly through induction of RANKL expression by osteoblastic or other cells (Dekel et al. 1981, Einhorn et al. 1995, Okada et al. 2000, Braun & Zwerina 2011). Indeed, thrombin itself must contribute to the inflammatory nature of the fracture site through induction of osteoblastic expression of IL6 and PGE₂, but here we demonstrate that thrombin also acts downstream from these factors through its direct inhibitory effect on osteoclast precursors and thus overrides its own apparent pro-osteoclastogenic effects on osteoblasts.

Thrombin and prothrombin have been identified in bone extracts using biochemical methods and in bone matrix using immunoelectron microscopy (Lecture et al. 2000, van den Bos et al. 2008, Hu et al. 2008), although contradictory data have been published as to whether prothrombin mRNA is expressed in bone (Song et al. 2005a, Karlstrom et al. 2011); thus, it is possible that active thrombin is present in normal bone. Another possible source of thrombin in the bone environment is skeletal muscle. Prothrombin is expressed by skeletal muscle, and cholinergic stimulation of muscle in vitro results in generation of active thrombin (Citron et al. 1997, Glazner et al. 1997, Kim et al. 1998). These observations suggest that the periosteal surfaces of bone in contact with muscle may be exposed to thrombin, especially during exercise. Thrombin released by exercising muscle may contribute to the anabolic effects of exercise on bone not only through
its effects on osteoblasts but also by suppressing osteoclast differentiation.

No clear information is available from in vivo studies concerning the role of thrombin in bone metabolism. Genetic elimination of prothrombin expression in mice causes a high rate of lethality at mid-gestation; the surviving animals are described as being born with no obvious abnormality but die soon after birth due to a bleeding disorder (Sun et al. 1998). Mice in which prothrombin expression is eliminated in adulthood die within 7 days of prothrombin depletion (Mullins et al. 2009). The skeletal phenotype has not been described for either of these strains of mice. Treatment with the anticoagulant heparin is associated with an increased incidence of fragility fractures in women (Mazziotti et al. 2010). In the current study, heparin failed to inhibit thrombin’s effect on osteoclastogenesis, but in addition to its direct interaction with thrombin, heparin also inhibits thrombin generation by acting at multiple stages of the coagulation cascade. The effect of heparin on fracture incidence may, therefore, be due to the reduced availability of thrombin to inhibit osteoclast differentiation, but as heparin interacts with many molecules in the bone environment, there are other possible mechanisms for heparin’s effect on fracture incidence.

It has been known for many years that thrombin exerts pro-anabolic effects on cells of the osteoblast lineage, but the results presented here demonstrate for the first time that thrombin also exerts anti-catabolic effects on cells of the osteoclast lineage. It can be concluded, therefore, that thrombin plays an overwhelmingly anabolic role in bone.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was partially supported by the National Health and Medical Research Council of Australia (Programme grant number 284233).

Author contribution statement
All authors conceived and designed the experiments. S S, C N P, L H L and L C W performed the experiments. S S, C N P, L H L and E J M analysed the data. S S, C N P, R N P and E J M wrote the paper.

Acknowledgements
The authors would like to thank Dr S R Coughlin (University of California, San Francisco) for making the PAR1-null mice available and Ms Su Toulson for the care of the mice.

References


Received in final form 5 February 2013

Accepted 18 February 2013

Accepted Preprint published online 18 February 2013